Here Is Why Tenet Healthcare (THC) Is One of the Cheap NYSE Stocks to Buy According to Analysts

Why It Matters

The earnings beat and strong cash generation reinforce Tenet’s valuation as a cheap, high‑yield healthcare stock, supporting analysts’ buy recommendations. Continued growth in ambulatory services and share‑repurchase momentum could boost earnings per share and investor returns.

Key Takeaways

• Tenet Q1 net income rose to $702M, up 73% YoY.
• Adjusted EBITDA steady at $1.162B, supporting growth outlook.
• Ambulatory Care revenue hit $1.32B, EBITDA $484M, 10.6% rise.
• Repurchased 1.35M shares for $318M, boosting EPS.
• Full-year Adjusted EBITDA forecast $4.485‑$4.785B reaffirmed.

Pulse Analysis

Tenet Healthcare (NYSE:THC) has emerged as a standout among low‑priced NYSE equities, delivering a first‑quarter earnings surge that eclipsed expectations. Net income climbed to $702 million, a 73% year‑over‑year jump, while adjusted EPS rose 10.6% to $4.82. The company’s disciplined expense management and solid revenue expansion across its Hospital Operations and Ambulatory Care divisions kept Adjusted EBITDA flat at $1.162 billion, underscoring the resilience of its core business model in a competitive healthcare landscape.

The Ambulatory Care segment, operating under United Surgical Partners International, was a key growth engine, posting $1.32 billion in net operating revenue and a 6.1% increase in Adjusted EBITDA to $484 million. This momentum was fueled by strategic acquisitions and a 5.3% rise in same‑facility patient service revenues, reflecting higher‑acuity procedures and a favorable service mix. Tenet’s cash flow strength was evident as operating activities generated $1.641 billion, enabling a $318 million share‑repurchase program that removed 1.35 million shares from the market, further enhancing earnings per share.

Analysts view Tenet’s reaffirmed full‑year Adjusted EBITDA guidance of $4.485‑$4.785 billion as a vote of confidence in its growth trajectory. The stock’s relative cheapness, combined with robust cash generation and a clear strategic focus on both organic and inorganic expansion, positions it as an attractive option for value‑oriented investors. While some commentators tout AI‑focused equities for higher upside, Tenet’s steady performance and dividend‑supporting cash flow offer a lower‑risk alternative in the healthcare sector, where demand remains insulated from broader economic cycles.